Steph & Co. Buys Shares of 25,000 Coherus BioSciences, Inc. (NASDAQ:CHRS)

Steph & Co. purchased a new position in Coherus BioSciences, Inc. (NASDAQ:CHRS) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 25,000 shares of the biotechnology company’s stock, valued at approximately $34,000.

Several other large investors also recently modified their holdings of CHRS. Systematic Financial Management LP acquired a new position in shares of Coherus BioSciences during the 3rd quarter valued at $28,000. Hsbc Holdings PLC raised its holdings in shares of Coherus BioSciences by 10.6% during the second quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 9,905 shares during the period. FMR LLC grew its stake in shares of Coherus BioSciences by 21.1% in the 3rd quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 39,204 shares during the period. Rhumbline Advisers increased its position in Coherus BioSciences by 19.5% in the 2nd quarter. Rhumbline Advisers now owns 154,904 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 25,241 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in Coherus BioSciences by 304.9% during the 2nd quarter. XTX Topco Ltd now owns 271,433 shares of the biotechnology company’s stock worth $470,000 after buying an additional 204,391 shares during the period. 72.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. StockNews.com cut Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Coherus BioSciences in a research note on Wednesday, December 4th. Finally, Robert W. Baird increased their price objective on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.38.

Coherus BioSciences Stock Down 2.7 %

Shares of CHRS stock opened at $1.42 on Friday. The firm has a market cap of $163.60 million, a P/E ratio of -17.75 and a beta of 0.82. The company has a 50 day moving average of $1.36 and a 200-day moving average of $1.27. Coherus BioSciences, Inc. has a 12-month low of $0.66 and a 12-month high of $2.97.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.